Aardvark Q2 2026: $36M net loss, cash runway into late 2027, and the path forward after a clinical hold
AARD has more than doubled off its 52-week low of $3.35.
Summary
Aardvark Therapeutics posted a Q2 2026 net loss of $14.4M, bringing first-half losses to $36M. Cash and equivalents stand at $73.9M, funding operations into late 2027. The company terminated its Phase 3 trials for ARD-101 and is evaluating next steps after an FDA clinical hold.
Key Events · Earnings and Guidance · AARD
-
Q2 2026 Net Loss of $14.4M
The net loss for Q2 2026 was $14.4M, roughly flat year-over-year, as a $2.7M decrease in R&D expenses was offset by a $1.9M increase in G&A. For the first half of 2026, the net loss reached $36.0M, up from $23.7M in the same period of 2025.
-
Cash Runway into Late 2027
Cash, cash equivalents, and short-term investments totaled $73.9M as of June 30, 2026. Management believes this is sufficient to fund operations into late 2027, though additional capital will be needed thereafter.
-
$150M ATM Facility Established
In March 2026, the company entered into an at-the-market equity offering sales agreement with Piper Sandler to sell up to $150M of common stock. As of June 30, 2026, no shares have been sold under the facility.
-
Clinical Hold and Trial Terminations
The FDA placed a full clinical hold on ARD-101 in May 2026 following reversible cardiac observations. Consequently, the company terminated the Phase 3 HERO and OLE trials in June 2026 and is now evaluating whether and how to pursue further development.
Analysis · AARD · Life Sciences
Aardvark's 10-Q confirms the termination of its Phase 3 trials for ARD-101 and the clinical hold, but the critical new disclosure is financial: the company burned $36.5M in operating cash during the first half of 2026, leaving $73.9M in cash and equivalents—enough to operate into late 2027. The filing also reveals a $150M at-the-market equity facility established in March 2026, retention bonuses for top executives, and a CFO trading plan. With no near-term catalysts, the company is now a clinical-stage biotech relying on its cash runway and potential future financing to survive while it evaluates next steps for its lead program.
At the time of this filing, AARD was trading at $7.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $157.3M. The 52-week trading range was $3.35 to $17.94. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.